CRNX - Crinetics Pharmaceuticals Inc
IEX Last Trade
53.03
0.330 0.622%
Share volume: 706,613
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$52.70
0.33
0.63%
Fundamental analysis
11%
Profitability
8%
Dept financing
3%
Liquidity
75%
Performance
0%
Performance
5 Days
-0.17%
1 Month
0.80%
3 Months
16.95%
6 Months
24.09%
1 Year
221.19%
2 Year
179.26%
Key data
Stock price
$53.03
DAY RANGE
N/A - N/A
52 WEEK RANGE
$15.76 - $55.78
52 WEEK CHANGE
$2.04
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: R. Scott Struthers
Region: US
Website: https://www.crinetics.com/
Employees: 194
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.crinetics.com/
Employees: 194
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
Recent news